Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenomic Landscape of Hematological Malignancies.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Among authors: heckman c. Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019. Cancer Cell. 2020. PMID: 32931743 No abstract available.
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O. Laukkanen S, et al. Among authors: heckman c. Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. Blood Cancer J. 2017. PMID: 28885610 Free PMC article. No abstract available.
Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.
Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg KJ, Lohi O, Nykter M, Heinäniemi M. Pölönen P, et al. Cancer Res. 2019 May 15;79(10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. Epub 2019 Apr 2. Cancer Res. 2019. PMID: 30940663
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.
Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. Kuusanmäki H, et al. Haematologica. 2020 Mar;105(3):708-720. doi: 10.3324/haematol.2018.214882. Epub 2019 Jul 11. Haematologica. 2020. PMID: 31296572 Free PMC article. No abstract available.
Immunogenomic Landscape of Hematological Malignancies.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Among authors: heckman c. Cancer Cell. 2020 Sep 14;38(3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9. Cancer Cell. 2020. PMID: 32649887 Free article.
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O. Malani D, et al. Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17. Leukemia. 2020. PMID: 32678289 No abstract available.
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, Thomson D, Schreiber A, Heckman CA, Koskenvesa P, Korhonen M, Porkka K, Branford S, Aittokallio T, Kankainen M, Mustjoki S. Adnan Awad S, et al. Leukemia. 2021 Apr;35(4):1087-1099. doi: 10.1038/s41375-020-01011-5. Epub 2020 Aug 11. Leukemia. 2021. PMID: 32782381 Free PMC article.
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.
Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T. Ianevski A, et al. Sci Adv. 2021 Feb 19;7(8):eabe4038. doi: 10.1126/sciadv.abe4038. Print 2021 Feb. Sci Adv. 2021. PMID: 33608276 Free PMC article.
474 results